Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort vs Spiriva vs Combination in COPD Group C with Bronchiectasis
NCT02546297Phase 4
Key facts
- Status
- Unknown
- Start
- Sep 2017
- Primary completion
- Sep 2020
- Countries
- 1
- Sponsor
- Shanghai Pulmonary Hospital
- Modality
- Orthosteric Ligands
- Drugs
- budesonidetiotropium
- Conditions
- chronic obstructive pulmonary disease (COPD)bronchiectasis
01
Overview
Phase 4, randomised trial of budesonide and tiotropium in chronic obstructive pulmonary disease (COPD) and bronchiectasis, sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Acute exacerbation at 12 months. Status: unknown.
02
Design
- Study design
- Randomized
03
Who it enrols
Patients 18 years or older diagnosed with COPD Group C and bronchiectasis, excluding those with active tuberculosis, severe respiratory disease, or uncontrollable diabetes.
04
Endpoints
Primary
Acute exacerbation
Beyond the preview
Go deeper on NCT02546297.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02546297.